Navigation Links
AEterna Zentaris Announces Results from Two Phase 3 Studies with Cetrorelix in Benign Prostatic Hyperplasia
Date:8/17/2009

monstrated at Week 52. These differences did not achieve statistical significance. Furthermore, a favorable trend on the IPSS, as compared to placebo, was seen in a sub-group of patients with large prostate glands (greater than 50 cm3) on entry to the study.

Tolerability of cetrorelix in study Z-033 was very good, as evidenced by the absence of major differences to placebo with regard to both clinical adverse events or changes in laboratory parameters. The most frequently reported adverse experiences included hot flushes, nasopharyngitis, injection site pain, and headache, which is what was seen in the safety study Z-041. In particular, the incidence of hot flushes was lower than was seen in study Z-041 (see below), and they were also reported by patients randomized to placebo.

Study Z-041

In the safety study Z-041, all patients received cetrorelix by intra-muscular (IM) injection at Weeks 0 and 2, and were followed up to Week 26. The primary endpoint was the incidence of possibly drug-related adverse events; efficacy parameters were evaluated as secondary endpoints. The study was conducted in 68 sites in the United States and Canada.

Cetrorelix was generally well tolerated. Adverse events were mostly mild and transient in intensity. Serious adverse events occurred in 12 patients, but none of these was assessed as possibly drug-related. The most frequently reported adverse experiences included hot flushes, nasopharyngitis, injections site pain, and headache. Hot flushes were reported by 49 patients and were mild and of short duration in the majority of patients. Only one patient experienced a severe episode. A questionnaire was used to assess the local tolerance of the IM injection and affirmed the acceptability of this route of administration.

Efficacy was assessed using the IPSS which showed an improvement from a mean score of 21.2 at baseline to 15.6 at Week 26. In 63% of the patients, the improvement was
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. AEterna Zentaris Reports Second Quarter 2009 Financial and Operating Results
2. AEterna Zentaris to Present at Upcoming Canaccord Adams 29th Annual Global Growth Conference
3. AEterna Zentaris to Announce Second Quarter 2009 Financial and Operating Results on August 11, 2009
4. AEterna Zentaris Partner, Keryx, Announces Agreement with FDA on a Special Protocol Assessment for Phase 3 Trial with Perifosine (KRX-0401) for the Treatment of Multiple Myeloma
5. AEterna Zentaris: New Data Published on its Ghrelin Antagonist Compound, AEZS-123 (JMV2959), Supports its Use in Alcohol Addiction
6. AEterna Zentaris Receives US$10 Million from Institutional Investors
7. AEterna Zentaris to Report Data from Safety Study of Phase 3 Program in Benign Prostatic Hyperplasia with Cetrorelix Ahead of Schedule
8. AEterna Zentaris Opens Extended Study for Cetrorelix in Benign Prostatic Hyperplasia
9. AEterna Zentaris Discloses Preliminary Phase 2 Trial Results for Perifosine in Combination with Radiotherapy for Non-Small Cell Lung Cancer
10. AEterna Zentaris Acquires All Assets from Ardana for Growth Hormone Secretagogue Compound, AEZS-130
11. AEterna Zentaris Presents Data Supporting Evaluation of AEZS-108 in Prostate Cancer at ASCO Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)...  Halozyme Therapeutics, Inc. (NASDAQ: HALO ) will ... quarter 2015 on Monday, August 10, 2015 at 4:30 ... president and chief executive officer, will lead the call. ... results for the second quarter 2015. The ... of Halozyme,s corporate website and a recording will be ...
(Date:8/3/2015)... 2015  ArroGen Group, an integrated advanced forensic ... Identification™ (FMID) technology Aug. 2-8 at the International ... Sacramento, Calif. FMID, a ... enforcement agents, district attorneys and government agencies to ... By analyzing chemical residues on fingerprints taken ...
(Date:8/3/2015)... At the 11th hour, London,s ... of Jude Liversage,s campaign so the seven-year-old ...      (Photo: http://photos.prnewswire.com/prnh/20150803/254228 ) ... The Selective Dorsal Rhizotomy (SDR) procedure reduced the spasticity ... wish to kick a ball around like his schoolmates. ...
(Date:8/3/2015)... Ga. , Aug. 3, 2015  MiMedx Group, ... company utilizing human amniotic tissue and patent-protected processes to ... Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic and ... present at the 35 th Annual Canaccord|Genuity Growth ... H. "Pete" Petit, Chairman and CEO, William C. ...
Breaking Biology Technology:Halozyme to Host Second Quarter 2015 Financial Results Conference Call 2ArroGen Previews New Fingerprint Molecular Identification Technology 2Cerebral Palsy Operation by The Portland Hospital Allows a Boy to Stand Properly for the First Time 2Cerebral Palsy Operation by The Portland Hospital Allows a Boy to Stand Properly for the First Time 3MiMedx To Present At 35th Annual Canaccord|Genuity Growth Conference 2
... /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE Amex: YMI, ... York), a licensee of several small molecule compounds ... of Health (NIH) Small Business Innovation Research (SBIR) ... Phase I awards to develop novel treatments for ...
... a bad rap for contributing to hypertension and cardiovascular disease. ... Sciences have discovered that sodium also plays a key role ... Tufts scientists have found a way to regenerate injured spinal ... an influx of sodium ions into injured cells. ...
... and global contributions to clean water and environmental causes, ... to invention and the pursuit of discovery, Professor Xiaoguang ... Stevens Institute of Technology at the university,s annual Convocation ... professor in the Charles V. Schaefer, Jr. School of ...
Cached Biology Technology:YM BioSciences licensee Pulmokine awarded NIH funding to develop small molecule drugs for pulmonary hypertension 2YM BioSciences licensee Pulmokine awarded NIH funding to develop small molecule drugs for pulmonary hypertension 3Sodium plays key role in tissue regeneration 2Sodium plays key role in tissue regeneration 3Xiaoguang Meng receives honorary master of engineering from Stevens 2Xiaoguang Meng receives honorary master of engineering from Stevens 3
(Date:7/31/2015)... , July 31, 2015 The 10 th ... be held by BGI from October 22-25, 2015, in ... The conference is celebrating its 10 th anniversary this ... of the world,s most influential annual meetings in the ,omics, ... enjoyable scientific gatherings. ICG-10 focuses on recent ...
(Date:7/23/2015)... Research and Markets ( http://www.researchandmarkets.com/research/rzzp3v/global_outlook_of ) ... Outlook of the Biometrics Industry 2015 " ... global biometrics market is likely to witness significant ... to the uptake of multiple technologies available. The ... the growth of biometrics in existing applications as ...
(Date:7/13/2015)... , July 13, 2015 Synaptics ... of human interface solutions, today announced sampling of ... and display driver integration (TDDI) product targeting smartphones ... first to combine Synaptics , best-in-class touch ... display driver technology developed in the company,s Japan ...
Breaking Biology News(10 mins):The 10th International Conference on Genomics (ICG-10) to Open in October 2Global Outlook of the Biometrics Industry 2015 2Global Outlook of the Biometrics Industry 2015 3Synaptics Announces Sampling of Second Generation TDDI Solutions 2Synaptics Announces Sampling of Second Generation TDDI Solutions 3
... volume of online scientific data, a new style of ... have a direct impact on scientists and clinicians. ... Biology and Faculty of 1000 Medicine, are each launching ... journals, called F1000 Reports, are unlike existing scientific journals ...
... wide-open spaces of the Flint Hills may no longer ... familiar grassland birds, according to research by a Kansas ... found that three bird species common to the Flint ... population decline in the face of extensive land-management practices ...
... epidemiological study of men and post-menopausal women primarily over ... associated with greater bone mineral density (BMD). Researchers at ... Aging (USDA HNRCA) at Tufts University found associations were ... significantly lower in men drinking more than two servings ...
Cached Biology News:World's experts identify the hottest trends in biology and medicine 2Birds in Flint Hills of Kansas, Oklahoma face population decline despite large habitat 2Birds in Flint Hills of Kansas, Oklahoma face population decline despite large habitat 3Moderate alcohol intake associated with bone protection 2Moderate alcohol intake associated with bone protection 3
... polymerase from Thermus aquaticus expressed in E. ... tube of 250 units enzyme/tube and Buffer ... is the same enzyme as AmpliTaq DNA ... proprietary separation process to ensure that contaminating ...
Our original highly-purified, robust Taq Polymerase which delivers consistently high yields and minimal background...
Taq DNA polymerase, 10,000U...
... AmpliTaq DNA Polymerase is the ... PCR process, a testimony to its overall ... profile makes it ideal for PCR applications. ... guarantee reproducible results. ,, AmpliTaq DNA ...
Biology Products: